Literature DB >> 15763542

Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.

Sascha Wagner1, Klaus Roemer.   

Abstract

Colorectal cancer accounts for approximately 10% of all new cancer cases reported worldwide. High dietary fiber intake has been associated with a reduced risk for this type of neoplasia, and much of this effect is ascribed to the histone acetylase (HDAC) inhibitor n-butyrate produced in the gastrointestinal tract. Natural chemopreventive and several new synthetic HDAC inhibitors exert multiple effects on tumor cells including the induction of differentiation, cell cycle arrest and apoptosis. Since cancer cells undergo mutational changes, it will be important to understand precisely which pathway gains or losses modulate or compromise HDAC inhibitor efficacy. We have recently documented that n-butyrate can provoke apoptosis in human HCT116 colorectal carcinoma cells independently of the p53 tumor suppressor and p21Waf inhibitor. Here, we have developed cell lines on the basis of HCT116 p21-/- cells and HCT116 cells in which the retinoblastoma tumor suppressor protein Rb has been specifically knocked down by antisense expression. The cells were exposed to the DNA-damaging drugs adriamycin (ADR) and etoposide or the HDAC inhibitors n-butyrate and trichostatin A (TSA). While the maximal apoptotic response, observed in the absence of p21Waf, was unaffected by the additional knockdown of Rb when cells were treated with ADR or etoposide, the toxicity of the HDAC inhibitors was significantly reduced. This indicates that hyperphosphorylated Rb itself, dissociated from E2F1 transcription factor, can contribute - directly or indirectly - to tumor cell apoptosis provoked by HDAC inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763542     DOI: 10.1016/j.bcp.2004.12.017

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: symbionts and immunopathology in chronic diseases: insights from evolution.

Authors:  P W Ewald
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

2.  RB goes mitochondrial.

Authors:  Laura D Attardi; Julien Sage
Journal:  Genes Dev       Date:  2013-05-01       Impact factor: 11.361

3.  Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.

Authors:  Chris Zhiyi Zhang; Yinghua Pan; Yun Cao; Paul B S Lai; Lili Liu; George Gong Chen; Jingping Yun
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

4.  Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways.

Authors:  Bodo Schniewind; Kirsten Heintz; Roland Kurdow; Ole Ammerpohl; Anna Trauzold; Doris Emme; Peter Dohrmann; Holger Kalthoff
Journal:  J Carcinog       Date:  2006-11-23

Review 5.  RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.

Authors:  Paola Indovina; Francesca Pentimalli; Nadia Casini; Immacolata Vocca; Antonio Giordano
Journal:  Oncotarget       Date:  2015-07-20

6.  Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.

Authors:  Jessica V Kaczmarek; Carley M Bogan; Janene M Pierce; Yuankai K Tao; Sheau-Chiann Chen; Qi Liu; Xiao Liu; Kelli L Boyd; M Wade Calcutt; Thomas M Bridges; Craig W Lindsley; Debra L Friedman; Ann Richmond; Anthony B Daniels
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-11-01       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.